Payment overview · 2025
General Payments
$1,530.62
83 reported records · 16 companies
Healthcare provider profile · identity verified
Mahmood Alam, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · WHITESBURG, KY · NPI 1083669741
Verified facts
What the public records show
CMS Open Payments records show Mahmood Alam, MD received $1,530.62 in general payments during 2025 across 83 reported records.
GlaxoSmithKline, LLC. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Glassia, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Gamunex-C by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Cuvitru by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $295.78 | 19.3% | 24 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $184.55 | 12.1% | 8 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $166.82 | 10.9% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $152.05 | 9.9% | 8 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $104.46 | 6.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.73 | 6.7% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $98.46 | 6.4% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $82.25 | 5.4% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $74.87 | 4.9% | 4 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $55.02 | 3.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $54.33 | 3.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.98 | 2.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.47 | 2.8% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $32.56 | 2.1% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $22.43 | 1.5% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $18.86 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,530.62 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $187.25 | 14 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $166.82 | 8 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $163.09 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $152.79 | 8 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $128.23 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $108.53 | 10 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $104.46 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $94.69 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $82.25 | 5 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $74.87 | 4 | 2025 |
Source payment records
|
|||||
| ARALAST Normalized: aralast |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $57.36 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $55.02 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $55.02 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GLASSIA glassia |
2025 | Glassia | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
95 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 48 |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
112 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 93 |
| Furosemide | Furosemide | 210 | 72 |
| Prednisone | Prednisone | 191 | 76 |
| Theophylline Er | Theophylline Anhydrous | 183 | 57 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 173 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 48 |
| Roflumilast | Roflumilast | 121 | 37 |
| Montelukast Sodium | Montelukast Sodium | 118 | 40 |
| Glassia | Alpha-1-Proteinase Inhibitor | 112 | 14 |
| Losartan Potassium | Losartan Potassium | 108 | 29 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 99 | suppressed |
| Levofloxacin | Levofloxacin | 98 | 66 |
| Symbicort | Budesonide/Formoterol Fumarate | 95 | 44 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 79 | suppressed |
| Potassium Chloride | Potassium Chloride | 79 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 75 | 26 |
| Diltiazem Hcl | Diltiazem Hcl | 72 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | 32 |
| Meloxicam | Meloxicam | 66 | 14 |
| Spironolactone | Spironolactone | 55 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 36 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 28 |
| Eliquis | Apixaban | 46 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 12 |
| Torsemide | Torsemide | 42 | 13 |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Bumetanide | Bumetanide | 34 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 33 |
| Breyna | Budesonide/Formoterol Fumarate | 30 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 29 | 12 |
| Omeprazole | Omeprazole | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lisinopril | Lisinopril | 26 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 25 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Dupixent Pen | Dupilumab | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 18 | 12 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Carvedilol | Carvedilol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Digoxin | Digoxin | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Gammagard S-D | Immun Glob G/Gly/Gluc/Iga 0-50 | 11 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 11 | suppressed |
| Xolair | Omalizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,530.62 · 83 records | GlaxoSmithKline, LLC. | AIRSUPRA, ARALAST, Arikayce, CHARTIS CATHETER, Cleerly Ischemia, Cleerly Labs, DUPIXENT, GLASSIA, Hillrom - Vest System Model 105 Home Care, NUCALA, OFEV, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, Xembify, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, Zemaira | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Glassia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error